Go Pro
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel Free BHST Stock Alerts

BioHarvest Sciences (BHST) Competitors

BioHarvest Sciences logo
$1.80 -0.10 (-5.26%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$1.81 +0.01 (+0.56%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BHST vs. MED, FTLF, SKIN, LFVN, and WNW

Should you buy BioHarvest Sciences stock or one of its competitors? BioHarvest Sciences's main competitors and comparable companies include Medifast (MED), FitLife Brands (FTLF), Beauty Health (SKIN), Lifevantage (LFVN), and Meiwu Technology (WNW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does BioHarvest Sciences compare to Medifast?

Medifast (NYSE:MED) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Medifast has a net margin of -8.08% compared to BioHarvest Sciences' net margin of -31.21%. Medifast's return on equity of -6.69% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Medifast-8.08% -6.69% -5.25%
BioHarvest Sciences -31.21%-58.30%-25.60%

BioHarvest Sciences has lower revenue, but higher earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medifast$385.79M0.36-$18.67M-$2.33N/A
BioHarvest Sciences$34.51M1.02-$11.14M-$0.52N/A

Medifast has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

In the previous week, Medifast had 2 more articles in the media than BioHarvest Sciences. MarketBeat recorded 5 mentions for Medifast and 3 mentions for BioHarvest Sciences. Medifast's average media sentiment score of 0.86 beat BioHarvest Sciences' score of 0.00 indicating that Medifast is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medifast
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioHarvest Sciences
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

95.5% of Medifast shares are owned by institutional investors. 3.7% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Medifast currently has a consensus target price of $12.00, suggesting a potential downside of 4.08%. BioHarvest Sciences has a consensus target price of $6.50, suggesting a potential upside of 261.11%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts clearly believe BioHarvest Sciences is more favorable than Medifast.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medifast
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Medifast and BioHarvest Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does BioHarvest Sciences compare to FitLife Brands?

BioHarvest Sciences (NASDAQ:BHST) and FitLife Brands (NASDAQ:FTLF) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

In the previous week, BioHarvest Sciences had 3 more articles in the media than FitLife Brands. MarketBeat recorded 3 mentions for BioHarvest Sciences and 0 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 1.00 beat BioHarvest Sciences' score of 0.00 indicating that FitLife Brands is being referred to more favorably in the news media.

Company Overall Sentiment
BioHarvest Sciences Neutral
FitLife Brands Positive

2.3% of FitLife Brands shares are held by institutional investors. 61.7% of FitLife Brands shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

FitLife Brands has a net margin of 6.15% compared to BioHarvest Sciences' net margin of -31.21%. FitLife Brands' return on equity of 18.10% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
BioHarvest Sciences-31.21% -58.30% -25.60%
FitLife Brands 6.15%18.10%7.63%

FitLife Brands has higher revenue and earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioHarvest Sciences$34.51M1.02-$11.14M-$0.52N/A
FitLife Brands$81.46M1.13$6.33M$0.6215.81

BioHarvest Sciences presently has a consensus target price of $6.50, suggesting a potential upside of 261.11%. FitLife Brands has a consensus target price of $18.00, suggesting a potential upside of 83.67%. Given BioHarvest Sciences' higher possible upside, research analysts clearly believe BioHarvest Sciences is more favorable than FitLife Brands.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
FitLife Brands
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

FitLife Brands beats BioHarvest Sciences on 11 of the 14 factors compared between the two stocks.

How does BioHarvest Sciences compare to Beauty Health?

Beauty Health (NASDAQ:SKIN) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Beauty Health has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, BioHarvest Sciences has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

In the previous week, Beauty Health had 2 more articles in the media than BioHarvest Sciences. MarketBeat recorded 5 mentions for Beauty Health and 3 mentions for BioHarvest Sciences. Beauty Health's average media sentiment score of 0.87 beat BioHarvest Sciences' score of 0.00 indicating that Beauty Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beauty Health
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioHarvest Sciences
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

93.3% of Beauty Health shares are owned by institutional investors. 35.5% of Beauty Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Beauty Health has higher revenue and earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Beauty Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beauty Health$300.80M0.30-$9.52M-$0.22N/A
BioHarvest Sciences$34.51M1.02-$11.14M-$0.52N/A

Beauty Health has a net margin of -9.79% compared to BioHarvest Sciences' net margin of -31.21%. Beauty Health's return on equity of -47.83% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Beauty Health-9.79% -47.83% -5.79%
BioHarvest Sciences -31.21%-58.30%-25.60%

Beauty Health currently has a consensus price target of $1.38, indicating a potential upside of 97.27%. BioHarvest Sciences has a consensus price target of $6.50, indicating a potential upside of 261.11%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Beauty Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beauty Health
1 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Beauty Health beats BioHarvest Sciences on 12 of the 16 factors compared between the two stocks.

How does BioHarvest Sciences compare to Lifevantage?

Lifevantage (NASDAQ:LFVN) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap consumer staples companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

35.3% of Lifevantage shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lifevantage has higher revenue and earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifevantage$182.59M0.42$5.07M$0.4015.28
BioHarvest Sciences$34.51M1.02-$11.14M-$0.52N/A

In the previous week, Lifevantage and Lifevantage both had 3 articles in the media. BioHarvest Sciences' average media sentiment score of 0.00 beat Lifevantage's score of -0.31 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lifevantage
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioHarvest Sciences
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lifevantage has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Lifevantage currently has a consensus target price of $5.50, indicating a potential downside of 9.98%. BioHarvest Sciences has a consensus target price of $6.50, indicating a potential upside of 261.11%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than Lifevantage.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifevantage
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Lifevantage has a net margin of 2.78% compared to BioHarvest Sciences' net margin of -31.21%. Lifevantage's return on equity of 21.56% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Lifevantage2.78% 21.56% 11.62%
BioHarvest Sciences -31.21%-58.30%-25.60%

Summary

Lifevantage beats BioHarvest Sciences on 9 of the 15 factors compared between the two stocks.

How does BioHarvest Sciences compare to Meiwu Technology?

Meiwu Technology (NASDAQ:WNW) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

BioHarvest Sciences has higher revenue and earnings than Meiwu Technology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meiwu Technology$7.08M8.89-$18.59MN/AN/A
BioHarvest Sciences$34.51M1.02-$11.14M-$0.52N/A

Meiwu Technology has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

BioHarvest Sciences has a consensus price target of $6.50, suggesting a potential upside of 261.11%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Meiwu Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Meiwu Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioHarvest Sciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Meiwu Technology has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -31.21%. Meiwu Technology's return on equity of 0.00% beat BioHarvest Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Meiwu TechnologyN/A N/A N/A
BioHarvest Sciences -31.21%-58.30%-25.60%

0.3% of Meiwu Technology shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, BioHarvest Sciences had 3 more articles in the media than Meiwu Technology. MarketBeat recorded 3 mentions for BioHarvest Sciences and 0 mentions for Meiwu Technology. Meiwu Technology's average media sentiment score of 0.00 equaled BioHarvest Sciences'average media sentiment score.

Company Overall Sentiment
Meiwu Technology Neutral
BioHarvest Sciences Neutral

Summary

BioHarvest Sciences beats Meiwu Technology on 7 of the 12 factors compared between the two stocks.

Get BioHarvest Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for BHST and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BHST vs. The Competition

Export
MetricBioHarvest SciencesPersonal Care Products IndustryConsumer Staples SectorNASDAQ Exchange
Market Cap$37.27M$23.61B$15.88B$12.73B
Dividend YieldN/A4.33%3.20%8.86%
P/E Ratio-3.4619.2813.5325.25
Price / Sales1.0213.16262,949.1797.64
Price / CashN/A27.1057.2652.26
Price / Book1.782.924.596.14
Net Income-$11.14M$1.13B$836.00M$349.01M
7 Day Performance-2.17%-1.48%-0.95%-0.31%
1 Month Performance-20.35%-0.73%-0.56%0.64%
1 Year Performance-76.35%-18.73%12.06%14.83%

BioHarvest Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BHST
BioHarvest Sciences
2.691 of 5 stars		$1.80
-5.3%		$6.50
+261.1%		-76.5%$37.27M$34.51MN/AN/A
MED
Medifast
1.5204 of 5 stars		$12.17
+0.1%		$12.00
-1.4%		-10.4%$136.18M$385.79MN/A870
FTLF
FitLife Brands
4.4392 of 5 stars		$9.79
-3.1%		$18.00
+83.9%		-43.0%$91.90M$81.46M15.6920
SKIN
Beauty Health
2.4797 of 5 stars		$0.69
-0.9%		$1.38
+100.7%		-65.2%$89.15M$300.80MN/A1,030
LFVN
Lifevantage
1.8285 of 5 stars		$6.36
-1.4%		$5.50
-13.5%		-55.0%$80.17M$182.59M15.90260

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BHST) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel